MX2023001071A - Tratamiento de la migraña. - Google Patents
Tratamiento de la migraña.Info
- Publication number
- MX2023001071A MX2023001071A MX2023001071A MX2023001071A MX2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A
- Authority
- MX
- Mexico
- Prior art keywords
- migraine
- treatment
- atogepant
- administration
- present disclosure
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 title abstract 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 abstract 1
- 229940070146 atogepant Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063103353P | 2020-07-29 | 2020-07-29 | |
| US202063070449P | 2020-08-26 | 2020-08-26 | |
| US202063087175P | 2020-10-02 | 2020-10-02 | |
| US202063092211P | 2020-10-15 | 2020-10-15 | |
| US202063129362P | 2020-12-22 | 2020-12-22 | |
| US202163201254P | 2021-04-20 | 2021-04-20 | |
| PCT/US2021/043791 WO2022026767A1 (en) | 2020-07-29 | 2021-07-29 | Treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001071A true MX2023001071A (es) | 2023-05-12 |
Family
ID=80003948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001071A MX2023001071A (es) | 2020-07-29 | 2021-07-29 | Tratamiento de la migraña. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12090148B2 (enExample) |
| EP (1) | EP4188375A4 (enExample) |
| JP (1) | JP2023535744A (enExample) |
| CN (1) | CN116390712A (enExample) |
| AU (1) | AU2021319090A1 (enExample) |
| BR (1) | BR112023001615A2 (enExample) |
| CA (1) | CA3190176A1 (enExample) |
| MX (1) | MX2023001071A (enExample) |
| WO (1) | WO2022026767A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| WO2023055758A1 (en) * | 2021-09-29 | 2023-04-06 | Pfizer Ireland Pharmaceuticals | Preventative treatment of migraine |
| CA3244873A1 (en) * | 2022-03-09 | 2023-09-14 | Allergan Pharmaceuticals International Limited | Preventive treatment for migraines |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US6103260A (en) | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| US7288559B2 (en) | 2003-03-14 | 2007-10-30 | Merck + Co, Inc. | Carboxamide spirohydantoin CGRP receptor antagonists |
| EP1606286B1 (en) | 2003-03-14 | 2011-05-11 | Merck Sharp & Dohme Corp. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| CA2543458A1 (en) | 2003-10-24 | 2005-05-12 | Josef Rettenmaier & Soehne Gmbh & Co., Kg | Process for co-spray drying agents with dry silicified mcc |
| US8003792B2 (en) | 2004-09-13 | 2011-08-23 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| EP1861399B1 (en) | 2005-03-14 | 2011-12-14 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
| CN101378731B (zh) | 2006-02-09 | 2014-03-05 | 默沙东公司 | Cetp抑制剂的聚合物制剂 |
| WO2007133491A1 (en) | 2006-05-09 | 2007-11-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| CA2689217C (en) | 2007-06-05 | 2016-02-16 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| NZ585347A (en) | 2007-10-18 | 2011-09-30 | Boehringer Ingelheim Int | Cgrp antagonists |
| EP2225237A2 (de) | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| JP2011511792A (ja) | 2008-02-05 | 2011-04-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体アンタゴニストのプロドラッグ |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| US20150023888A1 (en) | 2008-09-05 | 2015-01-22 | Map Pharmaceuticals, Inc. | Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| US8765763B2 (en) | 2009-06-05 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Substituted piperazines as CGRP antagonists |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| TWI501968B (zh) | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| WO2012064911A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane cgrp receptor antagonists |
| WO2012087777A1 (en) | 2010-12-22 | 2012-06-28 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide cgrp receptor antagonists |
| EP2654423B1 (en) | 2010-12-22 | 2016-12-07 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide cgrp receptor antagonists |
| WO2012122279A1 (en) | 2011-03-08 | 2012-09-13 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| WO2012129013A1 (en) | 2011-03-18 | 2012-09-27 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| EP2753640B1 (en) | 2011-09-08 | 2016-03-09 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| WO2013138418A2 (en) | 2012-03-14 | 2013-09-19 | Merck Sharp & Dohme Corp. | Process for making cgrp receptor antagonists |
| WO2013138413A1 (en) | 2012-03-14 | 2013-09-19 | Merck Sharp & Dohme Corp. | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| WO2013162769A1 (en) | 2012-04-25 | 2013-10-31 | Centric Research Institute | Sensitization composition and method of use |
| WO2013169563A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
| EP2846799B1 (en) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| US9227972B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam CGRP receptor antagonists |
| MY196014A (en) | 2013-03-15 | 2023-03-06 | Tonix Pharmaceuticals Inc | Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride |
| WO2015038736A2 (en) | 2013-09-16 | 2015-03-19 | Merck Sharp & Dohme Corp. | Formulations for cgrp receptor antagonists |
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| EP3102188A4 (en) | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| CN106456662A (zh) | 2014-02-24 | 2017-02-22 | 奥利金制药公司 | 口服给药的戊聚糖多硫酸盐的组合物及其使用方法 |
| KR20170043597A (ko) | 2014-08-22 | 2017-04-21 | 클로비스 온콜로지 인코포레이티드 | 루카파립의 고 용량 강도 정제 |
| CN107427493A (zh) | 2015-01-23 | 2017-12-01 | 格吕伦塔尔有限公司 | 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol |
| JP2018532728A (ja) | 2015-09-24 | 2018-11-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | （持続性）外傷後頭痛の予防、治療および低減 |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| JP7195262B2 (ja) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| US20200353088A1 (en) * | 2017-11-06 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof |
| US20190374520A1 (en) * | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| KR20210116560A (ko) | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
| US20200383983A1 (en) | 2019-04-18 | 2020-12-10 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| WO2021005494A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders |
| EP4034156A4 (en) | 2019-09-25 | 2024-01-24 | Allergan Pharmaceuticals International Limited | COMBINATION THERAPY WITH CGRP ANTAGONISTS |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| CA3244873A1 (en) | 2022-03-09 | 2023-09-14 | Allergan Pharmaceuticals International Limited | Preventive treatment for migraines |
-
2021
- 2021-07-29 MX MX2023001071A patent/MX2023001071A/es unknown
- 2021-07-29 CA CA3190176A patent/CA3190176A1/en active Pending
- 2021-07-29 CN CN202180054911.0A patent/CN116390712A/zh active Pending
- 2021-07-29 JP JP2023504814A patent/JP2023535744A/ja active Pending
- 2021-07-29 BR BR112023001615A patent/BR112023001615A2/pt unknown
- 2021-07-29 US US17/389,223 patent/US12090148B2/en active Active
- 2021-07-29 WO PCT/US2021/043791 patent/WO2022026767A1/en not_active Ceased
- 2021-07-29 AU AU2021319090A patent/AU2021319090A1/en active Pending
- 2021-07-29 EP EP21850713.5A patent/EP4188375A4/en active Pending
-
2024
- 2024-07-10 US US18/768,496 patent/US20250186422A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188375A4 (en) | 2024-07-24 |
| BR112023001615A2 (pt) | 2023-04-04 |
| JP2023535744A (ja) | 2023-08-21 |
| US20250186422A1 (en) | 2025-06-12 |
| US12090148B2 (en) | 2024-09-17 |
| US20220031686A1 (en) | 2022-02-03 |
| AU2021319090A1 (en) | 2023-03-02 |
| EP4188375A1 (en) | 2023-06-07 |
| CA3190176A1 (en) | 2022-02-03 |
| CN116390712A (zh) | 2023-07-04 |
| WO2022026767A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2020013352A (es) | Tratamiento para migrañas. | |
| MX2022007915A (es) | Compuestos de benzopirazol y analogos de estos. | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12016502246A1 (en) | Carboxamide derivatives | |
| BR112023001615A2 (pt) | Tratamento para enxaqueca | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| EP4467138A3 (en) | Therapeutic agents for neurodegenerative diseases | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| WO2021231931A8 (en) | Methods of treating sars-cov-2 infections | |
| PH12019550154A1 (en) | Azetidine derivative | |
| MX2021009717A (es) | Sulfonamidas biciclicas. |